

## REVIEWS

# Emergence and pandemic potential of swine-origin H1N1 influenza virus

Gabriele Neumann<sup>1</sup>, Takeshi Noda<sup>2</sup> & Yoshihiro Kawaoka<sup>1,2,3,4</sup>

**Influenza viruses cause annual epidemics and occasional pandemics that have claimed the lives of millions. The emergence of new strains will continue to pose challenges to public health and the scientific communities. A prime example is the recent emergence of swine-origin H1N1 viruses that have transmitted to and spread among humans, resulting in outbreaks internationally. Efforts to control these outbreaks and real-time monitoring of the evolution of this virus should provide us with invaluable information to direct infectious disease control programmes and to improve understanding of the factors that determine viral pathogenicity and/or transmissibility.**

The genomes of influenza viruses are plastic, owing to point mutations and reassortment events that contribute to the emergence of new variants or strains with epidemic or pandemic potential. Inasmuch, influenza A viruses have caused several pandemics during the last century, and continue to cause annual epidemics. Both epidemics and pandemics have substantial economic impact owing to the costs of prevention and treatment, work absenteeism, physician visits and excess hospitalizations. Therefore, a detailed understanding of the mechanisms that determine pathogenicity and interspecies transmission, combined with the availability of effective preventative and therapeutic measures, is critical to the control of influenza virus infections.

## Influenza A viruses

Influenza A viruses belong to the family Orthomyxoviridae. On the basis of the antigenicity of their haemagglutinin (HA) and neuraminidase (NA) molecules, they are classified into 16 HA subtypes (H1–H16) and 9 NA subtypes (N1–N9). Influenza A viruses contain a genome composed of eight segments of single-stranded, negative-sense RNA that each encodes one or two proteins (Fig. 1). The HA protein is critical for binding to cellular receptors and fusion of the viral and endosomal membranes (Fig. 2). Replication and transcription of viral RNAs (vRNAs) are carried out by the three polymerase subunits PB2, PB1 and PA, and the nucleoprotein NP. Newly synthesized viral ribonucleoprotein (vRNP) complexes are exported from the nucleus to the cytoplasm by the nuclear export protein (NEP, formerly called NS2) and the matrix protein M1, and are assembled into virions at the plasma membrane. The NA protein facilitates virus release from infected cells by removing sialic acids from cellular and viral HA and NA proteins. The functions of the ion channel protein M2, the interferon antagonist NS1, and the PB1-F2 protein are discussed in more detail later.

## Influenza pandemics

Influenza A viruses cause recurrent epidemics and global pandemics. Pandemics are typically caused by the introduction of a virus with an HA subtype that is new to human populations. Two mechanisms that are not mutually exclusive, reassortment and interspecies transmission, result in the introduction of viruses with new HA subtypes into human populations (Fig. 3). The recently emerged swine-origin

H1N1 influenza viruses (S-OIVs) are being detected in an increasing number of countries, and their global spread would undoubtedly result in a considerable number of infected individuals. At present, the mortality rate associated with S-OIV infections seems to be comparable to that of seasonal influenza virus outbreaks; however, increased surveillance activities could reveal a higher rate.

**‘Spanish’ influenza (H1N1).** The pandemic of 1918–1919 killed as many as 50 million people worldwide, and remains unprecedented in its severity. A first, mild wave in the spring of 1918 was replaced by a second wave in September to November of 1918 that resulted in mortality rates of over 2.5%, compared to less than 0.1% typically recorded for influenza outbreaks. A third wave with equally high mortality rates swept around the world in 1919.


The mortality pattern of the ‘Spanish’ influenza was unusual with high mortality rates for young adults. The atypical mortality pattern observed with the Spanish influenza remains unexplained to this day. In contrast, the morbidity pattern was similar to other pandemics—that is, children under the age of 15 experienced the highest attack rates.

The Spanish influenza virus was restricted to the respiratory tract; lack of systemic infection has also been observed in non-human primates experimentally infected with reconstituted 1918 virus<sup>1</sup>. Most patients died of bacterial pneumonia<sup>2</sup>, which may be attributed to the lack of antibiotics in 1918–1919; however, many others died owing to viral pneumonia.

Although the Spanish influenza virus was not isolated during the outbreak in 1918–1919, the genomic sequences of this virus were determined<sup>3,4</sup> and revealed an avian-like H1N1 virus that contains human-like signature amino acids in several proteins. The Spanish influenza virus lacks a multibasic HA cleavage site<sup>4</sup>, a hallmark of highly pathogenic avian influenza viruses (see ‘Role of HA in viral pathogenicity’).

Reverse genetics<sup>5</sup> allowed the re-creation of the Spanish influenza virus<sup>6</sup> and its characterization. The Spanish influenza virus elicits aberrant innate immune responses in mice<sup>7</sup> and in non-human primates<sup>1</sup>, a feature that it shares with highly pathogenic H5N1 viruses<sup>8</sup> and that probably contributes to pathogenicity and mortality in humans. Further studies showed that the HA protein<sup>9–11</sup>, the replication complex<sup>6,12,13</sup>, the NS1 protein<sup>14</sup>, and the PB1-F2 protein<sup>15</sup> contributed to its virulence, and that the HA and PB2 proteins were critical to its transmissibility<sup>13</sup>.

<sup>1</sup>Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin 53711, USA. <sup>2</sup>International Research Center for Infectious Diseases, <sup>3</sup>Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. <sup>4</sup>ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama 332-0012, Japan.



**Figure 1 | Schematic diagram of influenza A viruses.** Virions are decorated with two surface glycoproteins, HA and NA. The genome is composed of eight segments of single-stranded RNA that interact with the nucleoprotein and the components of polymerase complex (PB2, PB1 and PA).

**‘Asian’ influenza (H2N2).** The ‘Asian’ influenza originated in Southern China in February 1957. From there, it spread to Singapore (March 1957), Hong Kong (April 1957), Japan (May 1957), and the United States and the United Kingdom (October 1957). A second wave was detected in January 1958. In the United States, excess mortality was estimated to be 70,000. The pandemic was caused by a human/avian reassortant that introduced avian virus H2 HA and N2 NA genes into human populations (Fig. 3). Furthermore, the Asian influenza virus also possessed a PB1 gene of avian virus origin.

**‘Hong Kong’ influenza (H3N2).** In 1968, viruses of the H2N2 subtype were replaced by another human/avian reassortant that possessed an H3 HA gene of avian virus origin (Fig. 3). Again, the PB1 gene of the pandemic virus was derived from an avian virus. The virus was first isolated in Hong Kong in July 1968 and caused a pandemic in the


winters of 1968–1969 and 1969–1970. In the United States, an estimated 33,800 people died from the ‘Hong Kong’ influenza.

**‘Russian’ influenza (H1N1).** In May 1977, an influenza virus outbreak was reported in China that affected young adults in the northern hemisphere in the winter of 1977–1978. The outbreak was caused by influenza viruses of the H1N1 subtype that closely resembled viruses that had circulated in the early 1950s<sup>16</sup>, suggesting accidental release of this virus. The re-emerging H1N1 virus did not replace the H3N2 viruses circulating at the time, and both subtypes are co-circulating in humans to this day. Reassortment between viruses of these subtypes resulted in the emergence of H1N2 viruses in human populations in 2001. However, these H1N2 viruses have since disappeared.

### Highly pathogenic H5N1 influenza viruses


The infection of 18 individuals in Hong Kong in 1997 with highly pathogenic avian influenza viruses of the H5N1 subtype, which resulted in six fatalities<sup>17,18</sup>, marked the first reported fatal infections of humans with avian influenza viruses. This outbreak was brought under control with the depopulation of live birds in poultry markets in Hong Kong. After a period of local and sporadic outbreaks, a new outbreak started in 2003. H5N1 viruses have since reassorted frequently<sup>19–22</sup> and have spread to Europe and Africa and/or become enzootic in poultry populations in many Southeast Asian countries<sup>23</sup>.

The highly pathogenic H5N1 viruses have several remarkable features. First, they are not only lethal in chickens, but some highly pathogenic H5N1 viruses also kill waterfowl, the natural reservoir of influenza A viruses. Second, they replicate and cause lethal infection in mice without prior adaptation. Third, they have fatally infected several mammalian species. Non-lethal pig infections have been detected at low rates. Fourth, their pathogenicity in ferrets has increased over the years, indicating the acquisition of mutations that increase pathogenicity in mammalian species. Fifth, and of most concern, is their continued transmission to humans, resulting in severe respiratory infection with high mortality rates.



**Figure 2 | Schematic diagram of the influenza viral life cycle.** After receptor-mediated endocytosis, the viral ribonucleoprotein (vRNP) complexes are released into the cytoplasm and subsequently transported to the nucleus, where replication and transcription take place. Messenger RNAs are exported to the cytoplasm for translation. Early viral proteins, that is,

those required for replication and transcription, are transported back to the nucleus. Late in the infection cycle, the M1 and NS2 proteins facilitate the nuclear export of newly synthesized vRNPs. PB1-F2 associates with mitochondria. The assembly and budding of progeny virions occurs at the plasma membrane.



**Figure 3 | Emergence of pandemic influenza viruses.** The Spanish influenza was probably caused by the transmission of an avian influenza virus to humans. In 1957, the introduction of avian virus H2 HA, N2 NA and PB1 genes into human populations resulted in the Asian influenza. Similarly, the introduction of avian virus H3 HA and PB1 genes into human populations led to the Hong Kong influenza in 1968. In 1977, H1N1 viruses reappeared, which closely resembled strains that had been circulating in the mid-1950s.

As of 15 May 2009, 424 human infections with H5N1 have been confirmed, resulting in 261 deaths ([http://www.who.int/csr/disease/avian\\_influenza/country/cases\\_table\\_2009\\_05\\_15/en/index.html](http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_05_15/en/index.html)). Although several family clusters of H5N1 virus infection have been described, sustained human-to-human infection has not occurred. Hence, these H5N1 viruses are characterized by a high mortality rate but inefficient spread among humans; in contrast, S-OIVs seem to spread efficiently among humans but have caused a limited number of fatal infections.

Several reports indicate that highly pathogenic avian H5N1 viruses replicate mainly in the lower respiratory tract of humans<sup>8,24</sup>, and that the viral load correlates with the outcome of the infection<sup>8</sup>. Human H5N1 infections cause severe pneumonia and lymphopenia<sup>24–26</sup>, and are characterized by high levels of cytokines and chemokines<sup>8,27,28</sup>, a finding that was also confirmed in *in vitro* studies<sup>29,30</sup>. The induction of hypercytokinemia and hyperchemokinaemia may thus be associated with the level of virus replication<sup>8</sup>.

### Outbreak of swine-origin H1N1 viruses

Epidemiological data now indicate that an outbreak of influenza-like respiratory illness started in the Mexican town of La Gloria, Veracruz, in mid-February of 2009 (ref. 31; Table 1). In early April, public health authorities in Mexico began investigating high numbers of pneumonia/influenza-like illness, and informed the Pan American Health Organization (PAHO), the regional office of the World Health Organization (WHO), of a possible outbreak. In the United States, the Centers for Disease Control (CDC) identified S-OIVs in two specimens independently collected in Southern California in mid-April. On 23 April, the Public Health Agency of Canada also detected S-OIVs in specimens received from Mexico. Further cases and the finding that the Mexican and Californian cases were caused by similar viruses triggered alerts by the CDC and WHO on 24 April.

By the end of April, international spread and clusters of human-to-human transmission prompted the WHO to increase the pandemic alert from phase 3 to phase 4, and shortly after, to phase 5 (human-to-human spread in at least two countries, and signs of an imminent pandemic). In Mexico, substantial social-distancing measures were implemented. Moreover, massive campaigns were undertaken to educate the public about precautionary hygiene measures. As of 21 May 2009, 41 countries have reported 11,034 cases, including 85 deaths. Most cases outside Mexico and the United States have been caused by travellers from Mexico. Most infections seem to be mild and do not require hospitalization<sup>32</sup>. Careful monitoring will be necessary during the following months (that is, during the winter season in the southern hemisphere) to be prepared for the potential emergence of more virulent variants, as observed with the 1918 pandemic.

Data on the genetic composition of the virus became available soon after viral isolation from the initial cases<sup>32</sup>. The S-OIVs probably resulted from the reassortment of recent North American H3N2 and H1N2 swine viruses (that is, avian/human/swine ‘triple’ reassortant viruses) with Eurasian avian-like swine viruses<sup>32</sup> (Fig. 4). As a result, these viruses possess PB2 and PA genes of North American avian virus origin, a PB1 gene of human H3N2 virus origin, HA (H1), NP, and NS genes of classical swine virus origin, and NA (N1) and M genes of Eurasian avian-like swine virus origin (hence their original description as ‘quadruple’ reassortants). However, the human-like PB1 gene and the avian-like PB2 and PA genes have been circulating in pigs since 1997–1998 (when triple reassortant swine viruses were first isolated), and have probably undergone adaptation to pigs. These viruses do not possess markers associated with high pathogenicity (see the following sections on the role of viral proteins in pathogenicity for more details). Unlike negatively stained virions from S-OIVs that appeared spherical (<http://www.cdc.gov/h1n1flu/images.html>), our transmission electron microscopic analysis of cells infected with S-OIVs revealed virions of a distinctively filamentous shape (Fig. 5).

### Role of HA in viral pathogenicity

Influenza virus pathogenicity is multigenic, and the determinants of pathogenicity may differ among animal species. However, the HA protein has an important role in expressing high pathogenicity in many animal species. It mediates the binding of the virus to host cells, and the subsequent fusion of the viral and endosomal membranes for vRNP release into the cytoplasm. These functions assign a critical role to HA in the viral life cycle.


**Receptor distribution on host cells.** Influenza virus host specificity can be explained in part by the difference in receptor-binding specificity for human and avian influenza viruses. Human influenza viruses preferentially bind to sialic acid that is linked to galactose by an  $\alpha 2,6$ -linkage (SA $\alpha 2,6$ Gal)<sup>33</sup>. This preference is matched by SA $\alpha 2,6$ Gal on epithelial cells in the human trachea. In contrast, avian influenza viruses preferentially recognize SA $\alpha 2,3$ Gal that is matched by SA $\alpha 2,3$ Gal on epithelial cells in the intestinal tract of waterfowl<sup>34</sup> (the main replication site of avian influenza viruses).

The receptor-binding specificity of human and avian influenza viruses suggests that avian influenza viruses need to acquire the ability

**Table 1 | Timeline of swine-origin H1N1 virus outbreak (see also ref. 32)**

Date	Event
Mid-February	Outbreak of respiratory illness in La Gloria, Veracruz, Mexico <sup>31</sup>
12 April	Mexican public health authorities report outbreak in Veracruz to the PAHO
15 April	CDC identifies S-OIVs in the specimen of a boy from San Diego, California
17 April	CDC identifies S-OIVs in the specimen of a girl from Imperial, California
21 April	CDC alerts doctors to a new strain of H1N1 influenza virus
23 April	The Public Health Agency of Canada identifies S-OIVs in specimens from Mexico
24 April	WHO issues Disease Outbreak Notice
27 April	International spread and clusters of human-to-human transmission prompt WHO to raise the pandemic alert from phase 3 to 4
29 April	WHO raises the pandemic alert from phase 4 to 5 (human-to-human spread in at least two countries in one WHO region)
21 May	41 countries report 11,034 cases, including 85 deaths





**Figure 4 | Genesis of swine-origin H1N1 influenza viruses.** In the late 1990s, reassortment between human H3N2, North American avian, and classical swine viruses resulted in triple reassortant H3N2 and H1N2 swine viruses that have since circulated in North American pig populations. A triple reassortant swine virus reassorted with a Eurasian avian-like swine virus, resulting in the S-OIVs that are now circulating in humans.

to recognize human-type receptors to cause a pandemic. Indeed, the earliest isolates of the 1918, 1957 and 1968 pandemics possessed HA that, although of avian origin, recognized human-type receptors. In light of these findings, the infection of humans with highly pathogenic avian H5N1 viruses seemed to be surprising, particularly because the H5N1 viruses isolated from infected individuals in Hong Kong in 1997 preferentially recognized SA $\alpha$ 2,3Gal<sup>35</sup>. However, studies showed

avian-type receptors on human epithelial cells that line the respiratory bronchiole and the alveolar walls, but human-type receptors on human epithelial cells in nasal mucosa, paranasal sinuses, pharynx, trachea and bronchi<sup>36,37</sup>. Another study, however, showed the *ex vivo* infection of human upper respiratory organs with an H5N1 avian virus<sup>38</sup>. Still, the finding of avian-type receptors in human lungs explains the severe pneumonia seen in humans with highly pathogenic avian H5N1 viruses.


**HA receptor specificity.** The differences in receptor-binding specificity of human and avian viruses are determined by the amino acid residues in the HA receptor-binding pocket. Gln at position 226 and Gly at position 228 of H2 and H3 HAs confer binding to avian-type receptors, whereas Leu and Ser at these positions determine binding to human-type receptors. For H1 HAs, amino acids at position 190 and 225 (H3 numbering) determine receptor-binding specificity. HA-Asp 190 and HA-Asp 225 (found in human H1 HAs) confer binding to human-type receptors, whereas HA-Glu 190 and HA-Gly 225 (found in avian H1 HAs) confer binding to avian-type receptors<sup>39</sup>. Two viruses that differ in receptor recognition were circulating during the 1918 pandemic: one recognizing only human-type receptors that transmits efficiently among ferrets, and one recognizing both avian- and human-type receptors that transmits inefficiently in this animal<sup>40</sup>. The recently emerged S-OIVs possess the 'human virus'-type amino acid at positions 190 and 225, probably supporting efficient transmissibility of these viruses in humans. Interestingly, some S-OIV isolates possess an amino acid substitution at position 135 or 226 that has been found in H5N1 viruses isolated from humans and has been shown to affect receptor binding (S. Yamada and Y.K., unpublished data). These mutations may thus reflect viral adaptation in humans, an assumption that needs to be tested.

For H5N1 viruses, amino acid changes at positions 133, 138, 186, 192 and 227 (H3 numbering) have been identified in human isolates and confer human-type receptor recognition<sup>41–43</sup>. Experimental changes at positions 226 and 228 (Gln226Leu and Gly228Ser), but not at position 190 (Glu190Asp), resulted in the recognition of human-type receptors as well as avian-type receptors<sup>44</sup>; however, the respective amino acid changes at positions 226 and 228 have not been detected in human H5N1 virus isolates.

**HA cleavage.** HA cleavage is essential for viral infectivity because exposure of the amino terminus of HA2 (the so-called 'fusion peptide') mediates fusion between the viral envelope and the endosomal membrane, an essential step for vRNP release to the cytoplasm. HA cleavability is determined by the amino acid sequence at the cleavage site. Low pathogenic avian viruses and non-avian influenza viruses (with the exception of H7N7 equine influenza viruses) possess a single Arg residue at the cleavage site that is cleaved by proteases in the respiratory and/or intestinal organs, and hence restricts viral replication locally. In contrast, highly pathogenic H5 and H7 viruses possess several basic amino acids at the HA cleavage site<sup>45</sup> (Table 2). This motif is recognized by ubiquitous proteases, such as furin and PC6 (also known as PCSK5), and leads to systemic infections. For several outbreaks in poultry, increased pathogenicity of avian influenza viruses has been linked to the acquisition of multibasic HA cleavage sites, a finding that underscores the significance of the HA cleavage motif for virulence.

### Role of PB2 in pathogenicity and host specificity

Recently, the viral replication complex has been recognized as an important contributor to viral pathogenicity, probably by affecting viral growth. The amino acid at position 627 of the PB2 protein was first described as a host range determinant, on the basis of cell culture studies<sup>46</sup>. The respective amino acid change was shown to determine the pathogenicity of H5N1 influenza viruses in mice<sup>47</sup>. Viruses with lysine at this position were pathogenic in mice, whereas those with glutamic acid were non-pathogenic in these animals<sup>47</sup> (Table 2). Notably, almost all human influenza viruses possess lysine at this position, whereas most avian viruses (with the exception of the



**Figure 5 | Electron microscopic picture of recently emerged swine-origin H1N1 viruses.** Madin-Darby canine kidney cells were infected with A/California/04/09 (H1N1) virus and observed by thin-section electron microscopy 24 h later. Most virus particles showed a filamentous shape of more than 1  $\mu$ m in length. Scale bar, 1  $\mu$ m.

**Table 2 | Determinants of viral pathogenicity**

Protein	Position	Pathogenicity		Swine-origin H1N1 viruses	Function	Reference
		Low	High			
PB2	627	Glu	Lys	Glu	Replicative ability in some mammals, including humans	46, 47
	701	Asp	Asn	Asp	Nuclear import kinetics affecting replicative ability in mice	53, 55
PB1-F2	66	Asn	Ser	Truncated (11 aa)	Induction of apoptosis	74
HA	Cleavage site	Single basic aa	Multiple basic aa	Single basic aa	HA cleavage	45
NS1	92	Asp	Glu	Asp	Unknown (interferon response?)	65
	C terminus	Arg-Ser-Glu-Val, deletion	Glu-Ser-Glu-Val	11 C-terminal aa truncated	Unknown	69, 70

aa, amino acid(s).

'Qinghai Lake' lineage of H5N1 viruses and their descendants) possess glutamic acid at PB2-627. Lysine at position 627 of PB2 is now recognized as a determinant of viral pathogenicity in several mammalian species.

Several studies have addressed the mechanism by which PB2-Lys 627 affects virulence. The amino acid change does not affect tissue tropism in mice but viral replicative ability. This may result from an inhibitory activity in mammalian cells that prevents efficient replication by polymerase complexes possessing PB2-Glu 627 (ref. 48), and/or from inefficient interaction of PB2-Glu 627 with mammalian-type NP protein<sup>49</sup>. Viruses possessing PB2-Lys 627, but not those possessing PB2-Glu 627, grow efficiently in the upper respiratory tract of mammals<sup>50</sup>, which may be explained by the fact that PB2-Lys 627 confers efficient replication at 33 °C (the temperature of the upper airway in humans) whereas PB2-Glu 627 does not<sup>51</sup>. In contrast, both variants mediate efficient replication at 37 °C<sup>50,51</sup>. Collectively, these findings suggest that PB2-Lys 627 allows efficient replication not only in the lower, but also in the upper respiratory tract of mammals, a feature that may facilitate transmission. In fact, replacement of PB2-Lys 627 with Glu reduced the transmissibility of human influenza viruses in a guinea-pig model<sup>52</sup>.

The amino acid at position 701 of PB2 has also emerged as a determinant of virulence<sup>53,54</sup> (Table 2), a role probably related to its facilitation of binding of PB2 to importin  $\alpha$  (a cellular nuclear import factor) in mammalian cells<sup>55</sup>. The recently emerged S-OIVs possess the 'low pathogenic'-type amino acids at positions 627 and 701 (that is, Glu and Asp).

Recently, the PB2 and HA proteins of the Spanish influenza virus were shown to be critical for droplet transmission<sup>13</sup>. The underlying mechanism and the amino acids in PB2 that are critical for this function remain to be determined.

In addition to PB2, other components of the replication complex may also contribute to viral pathogenicity<sup>56</sup>. A recent study also suggested that the replication complex, particularly the PB1 protein, contributes to the virulence of the 1918 pandemic virus in ferrets<sup>12</sup>.

Structural data are now becoming available for the viral polymerase complex that may help in the interpretation of mutational analyses; in fact, two studies<sup>57,58</sup> showed that PB2-Lys 627 is part of a basic groove that is disrupted after replacement with Glu.

### Role of NS1 in viral pathogenicity

The NS1 protein is an interferon antagonist<sup>59,60</sup> that blocks the activation of transcription factors and IFN- $\beta$ -stimulated gene products, and binds to double-stranded RNA (dsRNA) to prevent the dsRNA-dependent activation of 2'-5' oligo(A) synthetase, and the subsequent activation of RNase L, an important player in the innate immune response. Recently obtained structural data are expected to help in the identification of domains that are critical for the biological functions of NS1.

Innate immune responses are stimulated after the recognition of a pathogen by a pathogen-recognition receptor. Several classes of pathogen-recognition receptors have now been described, including retinoic acid inducible gene-I (RIG-I, also known as DDX58) and melanoma differentiation antigen 5 (MDA5, also known as IFIH1),

and Toll-like receptors (TLRs) 3, 7 and 8. Influenza virus infections activate RIG-I signalling, which is counteracted by the viral NS1 protein<sup>61</sup>, possibly by forming a complex with RIG-I. Furthermore, influenza virus infection affects TLR7 (refs 62, 63) and TLR4 (ref. 64) signalling, and TLR4-deficient mice do not develop acute lung injury after infection with H5N1 viruses<sup>64</sup>. The direct contribution of NS1 to these signalling events is not known at present.

The NS1 proteins of H5N1 viruses confer resistance to the antiviral effects of interferon and are associated with high levels of pro-inflammatory cytokines<sup>27,28,30,65,66</sup>; the resulting cytokine imbalance probably contributes to the high mortality of H5N1 virus infections in humans. Several amino acids in NS1 have now been shown to affect virulence<sup>65,67,68</sup> (Table 2). The S-OIVs possess the low-pathogenic-type amino acid at these positions. However, available data suggest that these amino acid changes affect virulence in a strain-specific manner, whereas a multibasic HA cleavage sequence and PB2-Lys 627 seem to be universal determinants of viral pathogenicity.

The four carboxy-terminal amino acids of NS1 form a PDZ ligand domain motif that was identified by large-scale sequence analysis<sup>69</sup>. Introduction of the PDZ ligand domains of highly pathogenic H5N1 viruses or the pandemic 1918 virus into an otherwise human virus conferred slightly increased virulence in mice<sup>70</sup> (Table 2). This increase in virulence was not paralleled by increased interferon production. The S-OIVs lack the 11 C-terminal amino acids of NS1, and hence lack the PDZ domain motif. The biological significance of this finding is unknown at present.

### Role of PB1-F2 in viral pathogenicity

The PB1 gene of most avian and human influenza A viruses encodes a second protein, PB1-F2, that is expressed from the +1 reading frame<sup>71</sup>. The length of PB1-F2 of swine influenza viruses differs depending on their origin; classical swine viruses possess truncated PB1-F2 proteins of 8–11 amino acids, whereas Eurasian avian-like swine viruses possess full-length PB1-F2 proteins (87–89 amino acids). The S-OIVs encode a truncated PB1-F2 protein of 11 amino acids. PB1-F2 induces apoptosis, probably by interaction with two mitochondrial proteins<sup>71,72</sup>, enhances inflammation in mice, and increases the frequency and severity of secondary bacterial infections<sup>15</sup>. It may also affect virulence by interacting with the PB1 protein to retain it in the nucleus for efficient viral replication<sup>73</sup>. A recent study demonstrated that the amino acid at position 66 of PB1-F2 affects the pathogenicity of an H5N1 virus in mice<sup>74</sup> (Table 2). This finding is of great interest because the pandemic 1918 Spanish influenza virus possessed the 'high pathogenic'-type amino acid, and its replacement attenuated this virus<sup>74</sup>.

### Interspecies transmission

Wild waterfowl are the natural reservoir of influenza A viruses. Besides the continuing transmission of highly pathogenic avian H5N1 influenza viruses to humans, avian influenza A viruses were transmitted to pigs in Europe in 1979, to horses in China, and to seals. Moreover, an avian influenza virus reassorted with a human virus in pigs and transmitted from there to humans.

Human infections with avian or swine influenza viruses have been reported, but they have typically been self-limiting. It is in this context that the recently emerged H1N1 viruses, which are of swine origin and transmit among humans, raise great concern over an imminent pandemic.

Pigs can be naturally and experimentally infected with avian viruses and express both human- and avian-type influenza virus receptors on epithelial cells in trachea<sup>34</sup>, supporting the concept of a role as 'mixing vessel' in which human and avian viruses reassort. In North American pig populations, classical swine H1N1 virus dominated for nearly six decades. In 1997–1998, however, H3N2 triple human/avian/swine reassortant viruses emerged that have spread widely within North American pig populations. The emergence of human/avian/swine triple reassortant viruses in pigs further indicates that this species can be infected with human and avian influenza viruses and may provide a platform for reassortment. The triple reassortant viruses that emerged in North American pigs in 1997–1998 are the progenitors of the S-OIVs (Fig. 4).

### Prevention and control

For the prevention and control of influenza virus infections, both vaccines and antiviral drugs are available. Nonetheless, the global community is probably not well prepared for a pandemic: antiviral drugs may not be in sufficient supply and the virus may acquire resistance to the available antiviral drugs. On the other hand, the production of a vaccine to a newly emerging strain would take 3–6 months—during which time a virus could spread globally and substantially strain health care systems and the global economy.

**Antiviral drugs.** Two classes of antiviral drugs—ion channel inhibitors and neuraminidase inhibitors—are at present licensed for use against influenza A viruses.

Adamantanes (that is, amantadine hydrochloride and rimantadine) block the ion channel formed by the M2 protein, which is critical in the release of vRNPs into the cytoplasm. Resistance to adamantanes arises quickly and frequently, and most circulating human H1N1 and H3N2 viruses, some H5N1 viruses, and most European porcine H1N1, H1N2 and H3N2 viruses, are resistant to adamantanes. The S-OIVs are also resistant to ion channel inhibitors<sup>32</sup>.

Two neuraminidase inhibitors, oseltamivir and zanamivir, are licensed at present. Neuraminidase inhibitors interfere with the enzymatic activity of the NA protein, which is critical for the efficient release of newly synthesized viruses from infected cells.

In clinical trials, the emergence of resistance to NA inhibitors was rare, and oseltamivir-resistant influenza viruses were attenuated *in vitro* and *in vivo*. Hence, the dissemination of these viruses was not considered an important issue, despite the frequent use of the drug in some countries. However, a study in clinical settings indicated higher (18%) than expected rates of oseltamivir-resistance in children treated with this drug<sup>75</sup>. Recently, the rate of oseltamivir-resistant H1N1 influenza viruses in the United States has increased from 0.7% in the 2006–2007 influenza season to 98.5% in the 2008–2009 influenza season<sup>76</sup>. Similar numbers have been reported for other countries. Equally alarming, oseltamivir-resistant H5N1 viruses have been reported<sup>77,78</sup>. Oseltamivir-resistant human H1N1 viruses may have emerged in immunocompromised patients in which prolonged replication<sup>79–81</sup> may have resulted in the selection of mutations that increase the fitness of oseltamivir-resistant viruses. The S-OIVs are sensitive to neuraminidase inhibitors when tested *in vitro* in enzymatic assays<sup>32</sup>. Recent structural data provide an explanation for oseltamivir-resistance<sup>82</sup>, and suggest strategies for the design of improved compounds. In clinical settings, resistance to zanamivir has been reported for an influenza B virus isolated from an immunocompromised child<sup>83</sup>.

Several experimental antiviral drugs that target the NA or polymerase proteins are now in different stages of development.

Peramivir, an NA inhibitor that was developed through structure-based design<sup>84</sup>, is active in *in vitro* tests against viruses of all nine NA

subtypes, including highly pathogenic H5N1 viruses. Phase II clinical trials are now underway to assess the efficacy of intramuscularly administered peramivir against seasonal influenza.

CS-8958, a pro-drug of the new NA inhibitor R-125489 (ref. 85), is a long-acting neuraminidase inhibitor that was found to be effective in phase II clinical trials against seasonal influenza. We also found that CS-8958 has prophylactic and therapeutic efficacy against highly pathogenic H5N1 influenza viruses (M. Kiso, M. Yamashita and Y.K., unpublished data).

T-705 acts as a nucleoside analogue that interferes with the polymerase activity of influenza A, B and C viruses, but also other RNA viruses<sup>86</sup>. It protected mice against infection with highly pathogenic H5N1 viruses (M. Kiso, Y. Furuta and Y.K., unpublished data). Phase II clinical trials for use of T-705 against seasonal influenza viruses have been completed in Japan, and phase III clinical trials are scheduled.

Furthermore, monoclonal antibodies to HA are being developed for the treatment of influenza virus infections. In mice, some antibodies demonstrated prophylactic and therapeutic efficacy against lethal challenge with H5N1 virus<sup>87</sup>, suggesting monoclonal antibody treatment as an alternative strategy to treat influenza virus infections.

**Vaccines.** Seasonal influenza vaccines include human influenza A viruses of the H1N1 and H3N2 subtypes, and an influenza B virus. These vaccines need to be revised every 1–3 years to account for mutations in the HA and NA proteins of circulating viruses (antigen drift).

Inactivated vaccines have been used for many decades. Typically, reassortment is used to generate a seed virus that possesses the HA and NA segments of the circulating virus, and a variable number of segments from A/Puerto Rico/8/34 (H1N1) virus that confer efficient growth in embryonated chicken eggs. The allantoic fluid of embryonated, virus-infected chicken eggs is purified and concentrated by zonal centrifugation or column chromatography, and inactivated with formalin or  $\beta$ -propiolactone. Treatment with detergents or ether and the removal of vRNP complexes leads to split or subunit vaccines that are administered intramuscularly or subcutaneously.

In children and young adults, inactivated influenza vaccines show a 60–80% efficacy rate against laboratory/culture-confirmed influenza illness; this rate is lower in people over the age of 60, that is, the group of people that is most likely to die from influenza virus infections or associated complications. The development of improved influenza virus vaccines is thus clearly warranted.

A live attenuated influenza virus vaccine is now licensed in the United States for healthy individuals aged 2–49. In brief, serial passage of A/Ann Arbor/6/60 (H2N2) virus or B/Ann Arbor/1/66 at low temperatures resulted in viruses that are temperature-sensitive, cold-adapted, and attenuated. These viruses are then reassorted with currently circulating wild-type strains to generate seed viruses that possess the HA and NA genes of the circulating wild-type viruses in the background of the temperature-sensitive, cold-adapted and attenuated phenotypes.

Live attenuated vaccines elicit both humoral and cellular immune responses, and are therefore believed to be superior to inactivated vaccines. In fact, in infants and young children, live attenuated influenza vaccine provides better protection than inactivated vaccine<sup>88</sup>. At present, only egg-based vaccines are licensed for use in the United States. In case of a pandemic, however, eggs may be in short supply. In contrast, cell cultures are highly controllable systems that can be scaled-up for the mass production of vaccines, including those to highly pathogenic H5N1 viruses. The purity and immunogenicity of influenza vaccines produced in Madin-Darby canine kidney or African green monkey kidney cells match those of vaccines produced in embryonated chicken eggs. Cell-culture-based influenza vaccines have been approved for use in humans in Europe.

Recently, particular emphasis has been given to the development of vaccines to highly pathogenic H5N1 viruses. These viruses kill chicken embryos. Propagation of these viruses in eggs therefore results in low yields. To modify these viruses for efficient growth in



embryonated chicken eggs and safe handling by production staff, reverse genetics technologies<sup>5</sup> were used to replace the multibasic HA cleavage site with an avirulent-type HA cleavage site<sup>45</sup>, a known virulence factor. Reverse genetics then allowed the generation of a virus possessing the modified HA gene and the NA gene derived from the H5N1 virus and the remaining genes derived from A/Puerto Rico/8/34 virus. Clinical testing of an H5N1 vaccine candidate suggested low immunogenicity<sup>89</sup>, prompting the addition of adjuvants to vaccine candidates. In fact, aluminium hydroxide<sup>90,91</sup> or oil-in-water emulsions such as MF59 (refs 92, 93) or AS03 (ref. 94) resulted in considerable antigen-sparing effects. Adjuvanted vaccines also seem to induce broader immune responses, which may be a critical advantage with the emergence of new clades and subclades of H5N1 viruses.

Similarly, the NA and modified HA genes of highly pathogenic avian H5N1 viruses were combined with the remaining genes derived from the live attenuated influenza A virus<sup>95</sup>. To avoid the introduction of H5N1 HA and NA genes into human populations, live attenuated H5N1 vaccines should not be used before a pandemic. However, once H5N1 viruses are widespread in human populations, use of a live attenuated H5N1 vaccine, which is efficacious in non-human primates<sup>96</sup>, may be considered to overcome the low immunogenicity of inactivated vaccines.

Several new vaccine approaches are now in various stages of development. A 'universal' vaccine on the basis of the conserved ectodomain of the M2 protein confers protection against influenza virus infection in animals (reviewed in ref. 97). Various virus-like particles expressing the HA and NA proteins, some in combination with the M1 and M2 proteins, have been tested for their antigenicity and protective efficacy. A recent study demonstrated protection of ferrets against H5N1 virus infection by a virus-like particle expressing the HA, NA and M1 proteins of a heterologous virus<sup>98</sup>. Also, vector approaches have been pursued. In one example, replication-incompetent adenoviruses expressing an H5 HA protected mice against challenge with homologous and heterologous H5N1 viruses<sup>99,100</sup>. In alternative approaches, Newcastle disease and fowlpox viruses have been explored as vector systems; however, these systems have not been approved for use in humans.

## The future

Although much has been learned about influenza viruses, key questions still remain unanswered: for example, what factors determine interspecies transmission, reassortment and human-to-human transmission—factors that have accounted for past pandemics and will be critical in the emergence of new pandemic viruses. The first wave of pandemic Spanish influenza was characterized by relatively low pathogenicity in humans, but the virus presumably mutated into a more virulent form within a few months. Thus, careful monitoring of the S-OIVs during the upcoming winter season in the southern hemisphere is of critical importance to detect more virulent variants, should they arise. From a scientific perspective, the opportunity to watch virus evolution in real time may provide us with invaluable information on the factors that determine pathogenicity, and/or transmissibility. Furthermore, large-scale sequencing efforts, bioinformatics analyses, and the ability to experimentally test predictions with recombinant viruses will eventually provide insight into key features for the emergence of pandemic viruses. In the meantime, the development of improved and new antiviral drugs and vaccines will be critical to control influenza virus outbreaks.

Received 12 May; accepted 26 May 2009.

Published online 14 June 2009.

- Kobasa, D. *et al.* Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. *Nature* **445**, 319–323 (2007).
- Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J. Infect. Dis.* **198**, 962–970 (2008).
- Taubenberger, J. K., Reid, A. H., Krafft, A. E., Bijwaard, K. E. & Fanning, T. G. Initial genetic characterization of the 1918 "Spanish" influenza virus. *Science* **275**, 1793–1796 (1997).  
This is an important paper that describes the deciphering of the genomic sequence of the 1918 pandemic influenza virus.
- Reid, A. H., Fanning, T. G., Hultin, J. V. & Taubenberger, J. K. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. *Proc. Natl Acad. Sci. USA* **96**, 1651–1656 (1999).
- Neumann, G. *et al.* Generation of influenza A viruses entirely from cloned cDNA. *Proc. Natl Acad. Sci. USA* **96**, 9345–9350 (1999).  
This paper describes the artificial generation of influenza viruses, a breakthrough technology that allows the molecular characterization of influenza viruses and the generation of influenza virus vaccines.
- Tumpey, T. M. *et al.* Characterization of the reconstructed 1918 Spanish influenza pandemic virus. *Science* **310**, 77–80 (2005).  
This is a pivotal paper that describes the re-creation of the 1918 pandemic influenza virus.
- Kash, J. C. *et al.* Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. *Nature* **443**, 578–581 (2006).
- de Jong, M. D. *et al.* Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nature Med.* **12**, 1203–1207 (2006).  
This important paper describes high levels of cytokines in humans infected with highly pathogenic avian H5N1 viruses.
- Kobasa, D. *et al.* Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. *Nature* **431**, 703–707 (2004).
- Tumpey, T. M. *et al.* Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. *Proc. Natl Acad. Sci. USA* **99**, 13849–13854 (2002).
- Tumpey, T. M. *et al.* Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. *Proc. Natl Acad. Sci. USA* **101**, 3166–3171 (2004).
- Watanabe, T. *et al.* Viral RNA polymerase complex promotes optimal growth of 1918 virus in the lower respiratory tract of ferrets. *Proc. Natl Acad. Sci. USA* **106**, 588–592 (2009).
- Van Hoeven, N. *et al.* Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. *Proc. Natl Acad. Sci. USA* **106**, 3366–3371 (2009).
- Geiss, G. K. *et al.* Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. *Proc. Natl Acad. Sci. USA* **99**, 10736–10741 (2002).
- McAuley, J. L. *et al.* Expression of the 1918 influenza A virus PB1–F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. *Cell Host Microbe* **2**, 240–249 (2007).
- Nakajima, K., Desselberger, U. & Palese, P. Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. *Nature* **274**, 334–339 (1978).  
This paper established that the Russian influenza in 1977 was genetically closely related to viruses circulating in humans in the 1950s.
- Subbarao, K. *et al.* Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. *Science* **279**, 393–396 (1998).
- Claas, E. C. *et al.* Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. *Lancet* **351**, 472–477 (1998).
- Smith, G. J. *et al.* Emergence and predominance of an H5N1 influenza variant in China. *Proc. Natl Acad. Sci. USA* **103**, 16936–16941 (2006).
- Chen, H. *et al.* Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. *Proc. Natl Acad. Sci. USA* **103**, 2845–2850 (2006).
- Guan, Y. *et al.* Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. *Proc. Natl Acad. Sci. USA* **99**, 8950–8955 (2002).
- Li, K. S. *et al.* Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. *Nature* **430**, 209–213 (2004).  
This paper describes the frequent reassortment events of highly pathogenic avian H5N1 viruses that led to the emergence of the dominant 'genotype Z'.
- Ducatez, M. F. *et al.* Avian flu: multiple introductions of H5N1 in Nigeria. *Nature* **442**, 37 (2006).
- Tran, T. H. *et al.* Avian influenza A (H5N1) in 10 patients in Vietnam. *N. Engl. J. Med.* **350**, 1179–1188 (2004).
- The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. *N. Engl. J. Med.* **353**, 1374–1385 (2005).
- Chotpitayasunondh, T. *et al.* Human disease from influenza A (H5N1), Thailand, 2004. *Emerg. Infect. Dis.* **11**, 201–209 (2005).
- Peiris, J. S. *et al.* Re-emergence of fatal human influenza A subtype H5N1 disease. *Lancet* **363**, 617–619 (2004).  
This paper describes the re-emergence of human infections with highly pathogenic avian H5N1 viruses in 2003, and also emphasises the high concentrations of cytokines found in infected individuals.
- To, K. F. *et al.* Pathology of fatal human infection associated with avian influenza A H5N1 virus. *J. Med. Virol.* **63**, 242–246 (2001).
- Chan, M. C. *et al.* Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. *Respir. Res.* **6**, 135 (2005).

30. Cheung, C. Y. *et al.* Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? *Lancet* **360**, 1831–1837 (2002).
31. Fraser, C. *et al.* Pandemic potential of a strain of influenza A (H1N1): early findings. *Science* doi: 10.1126/science.1176062 (in the press).
32. Novel Swine-Origin Influenza A (H1N1) Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N. Engl. J. Med.* doi: 10.1056/NEJMoa0903810 (in the press).  
**This highly important paper presents the first summary of epidemiological and virological data on the new swine-origin H1N1 viruses.**
33. Rogers, G. N. & Paulson, J. C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. *Virology* **127**, 361–373 (1983).  
**This paper establishes differences between human and avian influenza viruses in receptor-binding specificity.**
34. Ito, T. *et al.* Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. *J. Virol.* **72**, 7367–7373 (1998).
35. Matrosovich, M., Zhou, N., Kawaoka, Y. & Webster, R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. *J. Virol.* **73**, 1146–1155 (1999).
36. Shinya, K. *et al.* Avian flu: influenza virus receptors in the human airway. *Nature* **440**, 435–436 (2006).
37. van Riel, D. *et al.* H5N1 virus attachment to lower respiratory tract. *Science* **312**, 399 (2006).
38. Nicholls, J. M. *et al.* Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. *Nature Med.* **13**, 147–149 (2007).
39. Stevens, J. *et al.* Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. *Science* **303**, 1866–1870 (2004).
40. Tumpey, T. M. *et al.* A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. *Science* **315**, 655–659 (2007).
41. Gambaryan, A. *et al.* Evolution of the receptor binding phenotype of influenza A (H5) viruses. *Virology* **344**, 432–438 (2006).
42. Yamada, S. *et al.* Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. *Nature* **444**, 378–382 (2006).
43. Auewarakul, P. *et al.* An avian influenza H5N1 virus that binds to a human-type receptor. *J. Virol.* **81**, 9950–9955 (2007).
44. Stevens, J. *et al.* Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. *Science* **312**, 404–410 (2006).
45. Kawaoka, Y. & Webster, R. G. Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. *Proc. Natl Acad. Sci. USA* **85**, 324–328 (1988).
46. Subbarao, E. K., London, W. & Murphy, B. R. A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. *J. Virol.* **67**, 1761–1764 (1993).
47. Hatta, M., Gao, P., Halfmann, P. & Kawaoka, Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. *Science* **293**, 1840–1842 (2001).
48. Mehle, A. & Doudna, J. A. An inhibitory activity in human cells restricts the function of an avian-like influenza virus polymerase. *Cell Host Microbe* **4**, 111–122 (2008).
49. Rameix-Welti, M. A., Tomoiu, A., Dos Santos Afonso, E., van der Werf, S. & Naffakh, N. Avian influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, is impaired in human cells during the course of infection. *J. Virol.* **83**, 1320–1331 (2009).
50. Hatta, M. *et al.* Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. *PLoS Pathog.* **3**, e133 (2007).
51. Massin, P., van der Werf, S. & Naffakh, N. Residue 627 of PB2 is a determinant of cold sensitivity in RNA replication of avian influenza viruses. *J. Virol.* **75**, 5398–5404 (2001).
52. Steel, J., Lowen, A. C., Mubareka, S. & Palese, P. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. *PLoS Pathog.* **5**, e1000252 (2009).
53. Li, Z. *et al.* Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. *J. Virol.* **79**, 12058–12064 (2005).
54. Gabriel, G. *et al.* Differential polymerase activity in avian and mammalian cells determines host range of influenza virus. *J. Virol.* **81**, 9601–9604 (2007).
55. Gabriel, G., Herwig, A. & Klenk, H. D. Interaction of polymerase subunit PB2 and NP with importin  $\alpha$ 1 is a determinant of host range of influenza A virus. *PLoS Pathog.* **4**, e11 (2008).
56. Salomon, R. *et al.* The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. *J. Exp. Med.* **203**, 689–697 (2006).
57. Tarendeau, F. *et al.* Host determinant residue lysine 627 lies on the surface of a discrete, folded domain of influenza virus polymerase PB2 subunit. *PLoS Pathog.* **4**, e1000136 (2008).
58. Kuzuhara, T. *et al.* Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding domain containing the pathogenicity-determinant lysine 627 residue. *J. Biol. Chem.* **284**, 6855–6860 (2009).
59. Garcia-Sastre, A. Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. *Virology* **279**, 375–384 (2001).
60. Garcia-Sastre, A. *et al.* Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. *Virology* **252**, 324–330 (1998).  
**This paper establishes the NS1 protein as an interferon antagonist.**
61. Pichlmair, A. *et al.* RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* **314**, 997–1001 (2006).
62. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* **303**, 1529–1531 (2004).
63. Lund, J. M. *et al.* Recognition of single-stranded RNA viruses by Toll-like receptor 7. *Proc. Natl Acad. Sci. USA* **101**, 5598–5603 (2004).
64. Imai, Y. *et al.* Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell* **133**, 235–249 (2008).
65. Seo, S., Hoffmann, E. & Webster, R. G. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. *Nature Med.* **8**, 950–954 (2002).
66. Guan, Y. *et al.* H5N1 influenza: a protean pandemic threat. *Proc. Natl Acad. Sci. USA* **101**, 8156–8161 (2004).
67. Jiao, P. *et al.* A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. *J. Virol.* **82**, 1146–1154 (2008).
68. Li, Z. *et al.* The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. *J. Virol.* **80**, 11115–11123 (2006).
69. Obenauer, J. C. *et al.* Large-scale sequence analysis of avian influenza isolates. *Science* **311**, 1576–1580 (2006).
70. Jackson, D., Hossain, M. J., Hickman, D., Perez, D. R. & Lamb, R. A. A new influenza virus virulence determinant: the NS1 protein four C-terminal residues modulate pathogenicity. *Proc. Natl Acad. Sci. USA* **105**, 4381–4386 (2008).
71. Chen, W. *et al.* A novel influenza A virus mitochondrial protein that induces cell death. *Nature Med.* **7**, 1306–1312 (2001).
72. Zamarin, D., Garcia-Sastre, A., Xiao, X., Wang, R. & Palese, P. Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. *PLoS Pathog.* **1**, e4 (2005).
73. Mazur, I. *et al.* The proapoptotic influenza A virus protein PB1-F2 regulates viral polymerase activity by interaction with the PB1 protein. *Cell. Microbiol.* **10**, 1140–1152 (2008).
74. Conenello, G. M., Zamarin, D., Perrone, L. A., Tumpey, T. & Palese, P. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. *PLoS Pathog.* **3**, e141 (2007).
75. Kiso, M. *et al.* Resistant influenza A viruses in children treated with oseltamivir: descriptive study. *Lancet* **364**, 759–765 (2004).
76. Poland, G. A., Jacobson, R. M. & Ovsyannikova, I. G. Influenza virus resistance to antiviral agents: a plea for rational use. *Clin. Infect. Dis.* **48**, 1254–1256 (2009).
77. Le, Q. M. *et al.* Avian flu: isolation of drug-resistant H5N1 virus. *Nature* **437**, 1108 (2005).
78. de Jong, M. D. *et al.* Oseltamivir resistance during treatment of influenza A (H5N1) infection. *N. Engl. J. Med.* **353**, 2667–2672 (2005).
79. Weinstock, D. M., Gubareva, L. V. & Zuccotti, G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. *N. Engl. J. Med.* **348**, 867–868 (2003).
80. Baz, M., Abed, Y., McDonald, J. & Boivin, G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. *Clin. Infect. Dis.* **43**, 1555–1561 (2006).
81. Ison, M. G., Gubareva, L. V., Atmar, R. L., Treanor, J. & Hayden, F. G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. *J. Infect. Dis.* **193**, 760–764 (2006).
82. Collins, P. J. *et al.* Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. *Nature* **453**, 1258–1261 (2008).
83. Gubareva, L. V., Matrosovich, M. N., Brenner, M. K., Bethell, R. C. & Webster, R. G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. *J. Infect. Dis.* **178**, 1257–1262 (1998).
84. Babu, Y. S. *et al.* BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. *J. Med. Chem.* **43**, 3482–3486 (2000).
85. Yamashita, M. *et al.* CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. *Antimicrob. Agents Chemother.* **53**, 186–192 (2009).
86. Furuta, Y. *et al.* In vitro and in vivo activities of anti-influenza virus compound T-705. *Antimicrob. Agents Chemother.* **46**, 977–981 (2002).
87. Sui, J. *et al.* Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. *Nature Struct. Mol. Biol.* **16**, 265–273 (2009).
88. Belshe, R. B. *et al.* Live attenuated versus inactivated influenza vaccine in infants and young children. *N. Engl. J. Med.* **356**, 685–696 (2007).
89. Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T. & Wolff, M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. *N. Engl. J. Med.* **354**, 1343–1351 (2006).
90. Bresson, J. L. *et al.* Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. *Lancet* **367**, 1657–1664 (2006).
91. Lin, J. *et al.* Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. *Lancet* **368**, 991–997 (2006).
92. Bernstein, D. I. *et al.* Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. *J. Infect. Dis.* **197**, 667–675 (2008).
93. Stephenson, I. *et al.* Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. *N. Engl. J. Med.* **359**, 1631–1633 (2008).
94. Levie, K. *et al.* An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. *J. Infect. Dis.* **198**, 642–649 (2008).



95. Suguitan, A. L. Jr *et al.* Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. *PLoS Med.* **3**, e360 (2006).
96. Fan, S. *et al.* Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. *PLoS Pathog.* **5**, e1000409 (2009).
97. Schotsaert, M., De, F. M., Fiers, W. & Saelens, X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. *Expert Rev. Vaccines* **8**, 499–508 (2009).
98. Mahmood, K. *et al.* H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. *Vaccine* **26**, 5393–5399 (2008).
99. Gao, W. *et al.* Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. *J. Virol.* **80**, 1959–1964 (2006).
100. Hoelscher, M. A. *et al.* Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. *Lancet* **367**, 475–481 (2006).

**Acknowledgements** We apologize to our colleagues whose critical contributions to influenza virus research could not be cited owing to the number of references permitted. We thank K. Wells for editing the manuscript. We also thank M. Ozawa and others in our laboratories who contributed to the data cited in this review. Our original research was supported by National Institute of Allergy and Infectious Diseases Public Health Service research grants; by the Center for Research on

Influenza Pathogenesis (CRIP) funded by the National Institute of Allergy and Infectious Diseases (Contract HHSN266200700010C), Grant-in-Aid for Specially Promoted Research, by a contract research fund for the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases from the Ministry of Education, Culture, Sports, Science, and Technology, by grants-in-aid from the Ministry of Health and by ERATO (Japan Science and Technology Agency). G.N. is named as co-inventor on several patents about influenza virus reverse genetics and/or the development of influenza virus vaccines or antivirals. Y.K. is named as inventor/co-inventor on several patents about influenza virus reverse genetics and/or the development of influenza virus vaccines or antivirals. Figures 1 and 2 were modified from Orthomyxoviruses: influenza, in Topley and Wilson's Microbiology and Microbial Infections: Virology (Hodder Arnold, 2005); Fig. 3 was modified from Orthomyxoviruses, in Fields Virology (Lippincott Williams & Wilkins, 2007).

**Author Contributions** G.N. wrote the manuscript. T.N. provided the electron microscopic picture. Y.K. also wrote the manuscript.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare competing financial interests: details accompany the full-text HTML version of the paper at [www.nature.com/nature](http://www.nature.com/nature). Correspondence should be addressed to Y.K. (kawaokay@svm.vetmed.wisc.edu).